About

As a manufacturer and supplier of innovative drugs that fully comply with legal requirements and international quality standards, the Skopin pharmaceutical plant (Skopinpharm) uses hi-tech production methods and participates in scientific research. For years, Skopinpharm has been the choice of multiple global pharma companies to localize their production.

15
Drugs
in our portfolio

Years
on the market

fulltime
employees
2015

The company built a facility with over 1000 m2 of floor space to host the four stages of blood products manufacturing in compliance with Octapharma AB technology. Over RUB 400 million were spent to build the biotech facility.

Within a year, Skopinpharm produced nearly 311 thousand packages of blood factors VIII, IX (about 200 million IU) with a total value of RUB 1.6 billion, with blood products supplied to all Russian regions as part of the Seven Nosologies program.

2016

Skopinpharm opened an upgraded RUB 1 billion building to produce antimicrobials, antiretrovirals, gastrointestinal medications, plasma-derived drugs and other medicinal products.

The company manufactured about 290 thousand packages of blood factors VIII, IX (about 192 million IU) valued at over RUB 1.58 billion, which covered 30 percent of the market's needs.

2018

The Ministry of Industry and Trade, the Ryazan Oblast Administration, Octapharma-Pharmimex LLC, Pharmimex JSC, and Skopinpharm signed a SPIC to launch a full cycle production of biopharmaceuticals, active ingredients and human plasma products, including those with no equivalent produced in Russia. The contract envisaged manufacturing nine unique products at the Skopinpharm site with a capacity of 600 thousand liters per year and upgrading production facilities, which requires RUB 6 billion of investment over 6-8 years.

2019

Skopinpharm and Novartis (Switzerland) agreed to transfer technologies and upgrade the Skopinpharm site to produce six innovative Novartis drugs for treating hematologic and oncological diseases, including breast cancer, melanoma, acute myelofibrosis, polycythemia vera, immune (idiopathic) thrombocytopenic purpura, and aplastic anemia.

Skopinpharm began to manufacture products in compliance with the Monitoring the movement of drugs (MDLP) system.


2020

Skopinpharm launched the construction of a new facility to produce drugs for treating hematologic and oncological diseases, like breast cancer, melanoma, acute myelofibrosis, polycythemia vera, immune (idiopathic) thrombocytopenic purpura, and aplastic anemia.

Skopinpharm was ranked the fastest growing company in the 2019 Forbes top 20 best pharmaceutical companies in Russia.


2021

The Ministry of Industry and Trade, the Ryazan Oblast Administration, and the Skopinsky District Administration entered into a RUB 3.6 billion Special Investment Contract (SPIC) with Skopinpharm to produce antitumor drugs (protein kinase inhibitors) and cancer diagnostics equipment. This was the first "SPIC 2.0" — now with pre-qualification —in Russia. Under this project, Skopinpharm intends to produce six hematology and oncology drugs, with five of them having no equivalent in Russia.

The Research Centre for Medical Genetics, Skopinpharm, and Novartis Pharma signed a memorandum to launch a pilot project for neonatal screening of rare diseases like spinal muscular atrophy (SMA) and primary immunodeficiency (PI).

Skopinpharm is a key participant in several SPICs
Skopinpharm: experience meets innovation
Process
Skopinpharm produces drugs using modern technical equipment.
To ensure the appropriate product quality, all the production steps
comply with standard operational procedures and the Good
Manufacturing Practice Rules.
Production
and storage
01 Full solid dosage forms production cycle
The company produces film-coated tablets, uncoated tablets, and capsules. Production lines are equipped with high-tech equipment from the world’s leading manufacturers: Bosch (Germany), Freund-Vector (USA), IMA (Italy), and Kilian (Germany).
02 Secondary packaging
The plant packs tablets, capsules, blood products, liquid dosage forms, and cytostatics. The company does the secondary packaging of cytostatics, monoclonal antibodies, and hormonal medications in separate rooms with airlocks for personnel, transfer hatches, and individual ventilation systems.
03 The HERMA machine
Labels vials. It attaches labels with the batch mark, production date, and shelf life.
04 The second viral inactivation
To inactivate viruses, vials with intermediate products are treated at 100°C in an autoclave.
05 Quality control department
Skopinpharm operates physicochemical and biological laboratories equipped with modern facilities.
06 Bulk product storage
Bulk products are kept at 2-8°С in cold stores with a total capacity of more than 80 pallets.
07 Finished product storage
Finished product stores can house over 120 pallets. Blood products are kept at the temperature of 20-25°С and at the humidity of 70%.

Are you
a healthcare professional?

Yes No